TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.
TOKYO, March 22 Japan's Nikkei fell in choppy
trade on Friday as financial stocks languished, reflecting more
cautious U.S. monetary policy, while the drug sector tumbled
after Eisai and Biogen said they will end their Alzheimer's drug